Select estrogens within the complex formulation of conjugated equine estrogens (Premarin®) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease
© Zhao and Brinton; licensee BioMed Central Ltd. 2006
Received: 10 November 2005
Accepted: 13 March 2006
Published: 13 March 2006
Results of the Women's Health Initiative Memory Study (WHIMS) raised concerns regarding the timing and formulation of hormone interventions. Conjugated equine estrogens (CEE), used as the estrogen therapy in the WHIMS trial, is a complex formulation containing multiple estrogens, including several not secreted by human ovaries, as well as other biologically active steroids. Although the full spectrum of estrogenic components present in CEE has not yet been resolved, 10 estrogens have been identified. In the present study, we sought to determine which estrogenic components, at concentrations commensurate with their plasma levels achieved following a single oral dose of 0.625 mg CEE (the dose used in the WHIMS trial) in women, are neuroprotective and whether combinations of those neuroprotective estrogens provide added benefit. Further, we sought, through computer-aided modeling analyses, to investigate the potential correlation of the molecular mechanisms that conferred estrogen neuroprotection with estrogen interactions with the estrogen receptor (ER).
Cultured basal forebrain neurons were exposed to either β-amyloid25–35 or excitotoxic glutamate with or without pretreatment with estrogens followed by neuroprotection analyses. Three indicators of neuroprotection that rely on different aspects of neuronal damage and viability, LDH release, intracellular ATP level and MTT formazan formation, were used to assess neuroprotective efficacy. Results of these analyses indicate that the estrogens, 17α-estradiol, 17β-estradiol, equilin, 17α-dihydroequilin, equilinen, 17α-dihydroequilenin, 17β-dihydroequilenin, and Δ8,9-dehydroestrone were each significantly neuroprotective in reducing neuronal plasma membrane damage induced by glutamate excitotoxicity. Of these estrogens, 17β-estradiol and Δ8,9-dehydroestrone were effective in protecting neurons against β-amyloid25–35-induced intracellular ATP decline. Coadministration of two out of three neuroprotective estrogens, 17β-estradiol, equilin and Δ8,9-dehydroestrone, exerted greater neuroprotective efficacy than individual estrogens. Computer-aided analyses to determine structure/function relationships between the estrogenic structures and their neuroprotective activity revealed that the predicted intermolecular interactions of estrogen analogues with ER correlate to their overall neuroprotective efficacy.
The present study provides the first documentation of the neuroprotective profile of individual estrogens contained within the complex formulation of CEE at concentrations commensurate with their plasma levels achieved after an oral administration of 0.625 mg CEE in women. Our analyses demonstrate that select estrogens within the complex formulation of CEE contribute to its neuroprotective efficacy. Moreover, our data predict that the magnitude of neuroprotection induced by individual estrogens at relatively low concentrations may be clinically undetectable and ineffective, whereas, a combination of select neuroprotective estrogens could provide an increased and clinically meaningful efficacy. More importantly, these data suggest a strategy for determining neurological efficacy and rational design and development of a composition of estrogen therapy to alleviate climacteric symptoms, promote neurological health, and prevent age-related neurodegeneration, such as AD, in postmenopausal women.
Multiple factors have been hypothesized as potential contributors to the disparity between observational studies, which found that estrogen/hormone therapy (ET/HT) is associated with improved cognitive function and/or reduced risk (20–50%) of developing Alzheimer's disease (AD) in postmenopausal women [1–6], and the randomized double blind clinical trial, Women's Health Initiative Memory Study [7–10], or trials of ET/HT in women with existing AD [11–14], where ET/HT showed no benefit and in some instances adverse outcomes on neurological health in postmenopausal women. Prime among those factors are the temporal parameters of ET/HT intervention and the ET/HT formulation.
Using a prevention model paradigm in which cultured primary neurons were treated with conjugated equine estrogens (CEE) prior to exposure to degenerative insults associated with AD, our earlier work demonstrated that CEE significantly protected neurons against toxic insults-induced cell death . In a treatment model paradigm, in which primary neurons were first exposed to β-amyloid25–35 followed by CEE treatment, neurons treated with CEE had a slower rate of degeneration but were not protected against β-amyloid25–35-induced cell death . Our in vitro model systems that simulate prevention versus treatment modes of estrogen exposure indicate a healthy cell bias of estrogen action in neurons [16, 17], and they provide us a lens through which to view the clinical data from both observational studies and trials. That is, women who received ET/HT at the time of menopause, in a prevention mode before extensive age-associated degeneration occurs, exhibited improved cognitive function and a lower risk of developing AD than women who had never received ET/HT, which is consistent with most observational analyses [1–6, 18–21]. In contrast, when women received ET/HT in their 60's or 70's, when age-associated insults have already occurred in some women, or following the onset of AD, ET/HT had no benefit to or even exacerbated the degenerative state, as demonstrated in a number of clinical trials, including the WHIMS [7–14]. These analyses suggest that ET/HT can be effective in preventing rather than treating age-related neuronal decline and degeneration.
Timing of ET/HT intervention is paralleled by the crucial issue of ET/HT formulation. First, the question of which progestin to use in ET/HT remains unresolved. Results of the WHIMS CEE plus medroxyprogesterone acetate (MPA) trial indicated an increased risk (hazard ratio: 2.05) of developing dementia [8, 10], whereas the CEE alone trial showed no statistically significant benefit or detriment, although there was a trend towards increased risk (hazard ratio: 1.49) of developing dementia [7, 9]. The difference in severity of adverse outcomes between the CEE plus MPA trial and CEE alone trial suggests that the addition of MPA to the estrogen formulation exacerbated neurological decline in postmenopausal women aged 65 years or older. These clinical findings are consistent with our in vitro data demonstrating that MPA antagonized 17β-estradiol-induced mechanisms of memory and neuroprotection. In contrast, progesterone was both neuroprotective alone and synergized with 17β-estradiol [22–25].
The current study was undertaken to determine the impact of the above 10 estrogenic components within CEE on measures of neuronal viability and survival, at concentrations commensurate with their plasma levels achieved following a single oral dose of 0.625 mg CEE . Subsequently, combinations of neuroprotective estrogens were assessed to determine whether coadministration of select estrogenic molecules within CEE were more efficacious than single molecule formulations. Primary cultures of basal forebrain neurons were used due to their vulnerability to neurodegeneration in the aging or AD brain [34, 35], and all analyses were conducted with a comparative reference to 17β-estradiol. Further, computer-aided modeling analyses were conducted to investigate the potential correlation among the neuroprotective efficacy of estrogens, their structures and estrogen interactions with ER.
Select estrogens within CEE are neuroprotective against β-amyloid25–35-induced toxicity in primary basal forebrain neurons
Efficacy of select estrogens within CEE to reduce LDH release following exposure to β-amyloid25–35 in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 24 hr exposure to 8 μg/ml β-amyloid25–35. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr followed by determination of LDH release into the medium. Data are represented as mean ± SEM (n = 7 – 24 from 3 separate experiments). ** P < 0.01 and *** P < 0.001 compared to β-amyloid25–35 alone-treated cultures.
LDH Release (% of β-amyloid25–35 alone group)
36.11 ± 1.60***
100.00 ± 2.26
86.62 ± 2.99**
84.20 ± 1.47***
89.01 ± 1.74**
81.49 ± 3.06***
89.96 ± 3.88**
101.53 ± 2.00
99.33 ± 4.43
85.82 ± 2.07***
Differential neuroprotective profile with intracellular ATP level as the neuronal viability index
Efficacy of select estrogens within CEE to sustain the intracellular ATP level following exposure to β-amyloid25–35 in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 24 hr exposure to 8 μg/ml β-amyloid25–35. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr followed by determination of the intracellular ATP level. Data are represented as mean ± SEM (n = 7 – 24 from 3 separate experiments). ** P < 0.01 and *** P < 0.001 compared to β-amyloid25–35 alone-treated cultures.
ATP Level (% of β-amyloid25–35 alone group)
203.37 ± 11.67***
100.00 ± 2.07
103.83 ± 3.76
131.32 ± 4.56**
114.58 ± 3.56
96.44 ± 4.07
110.00 ± 2.75
110.75 ± 2.46
128.84 ± 4.14**
125.05 ± 1.42**
Neuroprotective effects of select estrogens against glutamate-induced excitotoxicity
Efficacy of select estrogens within CEE to reduce LDH release following exposure to excitotoxic glutamate in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 5 min exposure to 200 μM glutamate. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr followed by determination of LDH release into the medium. Data are represented as mean ± SEM (n = 11 – 14 from 3 experiments). ** P < 0.01 and *** P < 0.001 compared to glutamate alone-treated cultures.
LDH Release (% of glutamate alone group)
47.49 ± 2.69***
100.00 ± 2.89
57.55 ± 3.00**
64.02 ± 3.03**
85.46 ± 3.22
66.05 ± 2.74**
Efficacy of select estrogens within CEE to sustain the intracellular ATP level following exposure to excitotoxic glutamate in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 5 min exposure to 200 μM glutamate. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr followed by determination of the intracellular ATP level. Data are represented as mean ± SEM (n = 11 – 14 from 3 experiments). ** P < 0.01 compared to glutamate alone-treated cultures.
ATP Level (% of glutamate alone group)
128.72 ± 4.21**
100.00 ± 1.50
109.38 ± 2.91
108.44 ± 1.86
93.41 ± 3.85
111.80 ± 4.51
Neuroprotective effects of select estrogens based on MTT reduction measurements
Efficacy of select estrogens within CEE to reduce LDH release and sustain MTT reduction following exposure to excitotoxic glutamate in basal forebrain neurons. Neuronal cultures were pretreated with indicated estrogens for 4 days followed by a 5 min exposure to 200 μM glutamate. The culture medium was replaced and cultures were allowed to incubate for an additional 24 hr followed by determination of LDH release into the medium and MTT reduction. Data are represented as mean ± SEM (n = 17 – 33 from 3 experiments). * P < 0.05, ** P < 0.01 and *** P < 0.001 compared to glutamate alone-treated cultures.
LDH Release (% of glutamate alone group)
MTT Reduction (% of glutamate alone group)
41.59 ± 2.85***
194.49 ± 3.52***
100.00 ± 1.25
100.00 ± 1.51
83.03 ± 1.91**
98.06 ± 1.39
92.29 ± 1.91**
98.81 ± 1.93
86.37 ± 2.19**
105.76 ± 3.36
88.00 ± 2.55**
103.62 ± 1.86
90.68 ± 2.21**
102.22 ± 2.25
84.74 ± 3.02**
91.10 ± 5.63
90.87 ± 2.99*
113.17 ± 3.65
86.69 ± 2.20**
102.88 ± 2.71
Coadministration of select neuroprotective estrogens exerts greater efficacy against neurotoxic insult
Correlation between the interactions with ER and the neuroprotective profile of estrogen analogues
Intermolecular interaction between estrogens and ERα. avan der Waals energy; belectrostatic energy.
The neuroprotective profile of select estrogens within CEE that are suggestive for clinical use
Taken together, the present study demonstrates that select estrogenic components within CEE are protective against neurodegenerative insults induced by β-amyloid25–35 and excitotoxic glutamate in primary basal forebrain neurons. Results of these analyses indicate that 3 of the 10 estrogens tested, 17β-estradiol, equilin and Δ8,9-dehydroestrone, were consistently neuroprotective against β-amyloid25–35-induced decline in membrane integrity and mitochondrial function. Further, our analyses indicate that coadministration of these neuroprotective estrogens can enhance the magnitude of their neuroprotective efficacy as evidenced by the observation that the above 3 estrogens, when used individually, were ineffective at the plasma dose whereas these same estrogens, when used in combination, were protective against excitotoxic glutamate-induced neuronal compromise of both the plasma membrane and mitochondrial function. The neuroprotective effects of combined estrogens could be synergistic in instances where a single estrogen exhibits no impact on neuronal viability, while the combined use of several estrogens induces a significant increase of neuronal viability. Another possibility is that since the concentrations of estrogens used in the present study were very low, consistent with the therapeutic plasma levels of these estrogens following a single oral dose of 0.625 mg CEE, the capacity of multiple estrogens to induce significant increase in markers of neuronal viability may simply be a threshold concentration issue. The low concentration of a single estrogen was not sufficient to increase neuronal defense mechanisms whereas a combination of multiple estrogens reached threshold concentration. In addition to the threshold concentration issue, the estrogen specificity requirement impacts estrogen efficacy as well, since not all estrogens were proved to be neuroprotective based on a quite sensitive measurement of LDH release.
Overall, the present study indicates that a combination of select neuroprotective estrogens at low concentrations could provide better therapeutic potential than administering a single estrogen. A formulation composed of both neuroprotective and non-protective estrogenic components may result in a compromised outcome through a competitive mechanism with multiple estrogens of varying efficacy competing for the same site of action with varying degrees of activation capability in the brain. Data from the present study suggest that, instead of using a complex formulation of estrogens with varying degrees of efficacy in the brain, using a formulation that is selectively efficacious for the brain could yield greater therapeutic benefit to promote neurological health and prevent neurodegeneration in postmenopausal women.
Different biochemical markers based on different cellular processes may yield different responses
An important issue emerging from the present study relates to the biochemical markers used to assess the neuronal viability. For the LDH release assay, since the extracellular LDH remains stable for days, the magnitude of relative release of LDH correlates in linear fashion with the number of damaged neurons in the culture. The LDH release assay has been demonstrated to be a reliable indicator of cellular plasma membrane integrity and proved to be a consistent marker for estrogen efficacy in protecting neuronal membrane against neurotoxic insults in neurons . The ATP and MTT assays are considered reliable indicators of cellular metabolic activity dependent upon mitochondrial functional integrity determined by the measurements of the cellular mitochondrial energy utilization and respiratory chain activity, respectively. In the present study, select estrogens that were neuroprotective against LDH release induced by neurotoxic β-amyloid25–35 or excitotoxic glutamate were ineffective in promoting neuronal metabolic integrity, indicating that neuronal membrane damage may be more easily protected and repaired than damage to neuronal mitochondrial function. The combined use of these select estrogens led to an enhanced neuroprotective efficacy, indicating that the neuroprotective efficacy exhibited by multiple estrogens could reach the threshold concentration sufficient for the maintenance of neuronal mitochondrial function. These analyses implicate a molecule that can protect neurons against plasma membrane damage reflected by the measurement of the LDH level in the culture medium does not necessarily have the same potential to maintain or reduce the damage to the cellular mitochondrial function. Further, these data suggest that one cannot expect these biochemical neuroprotective indexes to have equivalent responses to a chemical molecule because they are biochemical markers of distinct cellular processes. Therefore, investigations using multiple biochemical neuroprotective markers based on different cellular processes are necessary in order to determine the overall neuroprotective potential of an estrogenic molecule against the toxic insults in neurons.
In addition, it should be noted that the profile of neuroprotective efficacy of test estrogens demonstrated in the present study is associated with the therapeutic plasma levels of these estrogens achieved following a single oral dose of 0.625 mg CEE. For example, although pretreatment with 10 pg/ml of 17β-estradiol was effective in protecting neurons against β-amyloid25–35-induced intracellular ATP decline, an indication of neuronal mitochondrial dysfunction, such protection was not significant in neurons exposed to excitotoxic glutamate. One possible explanation is that compromise of neuronal mitochondrial function resulting from a slowly degenerative process, such as β-amyloid exposure, allows for cellular neuroprotective adaptations following β-amyloid exposure, whereas a rapid neurodegenerative insult, such as excitotoxic glutamate exposure, does not allow for upregulation of neuronal defense mechanisms but instead relies solely on existing levels of defense mechanisms. Consistent with this hypothesis, both β-amyloid and excitotoxic glutamate-induced neurodegeneration are associated with calcium influx, however the temporal pattern and magnitude of the calcium rise are quite different. β-Amyloid exposure induces a slow and modest rise in intracellular calcium whereas excitotoxic glutamate induces a rapid and robust rise in intracellular calcium . However, the calcium-mediated neuronal dysfunction in response to excitotoxic glutamate can be overcome with either the combined use of multiple estrogens, as demonstrated in the present study, or the administration of a higher concentration of a single estrogen, such as 17β-estradiol, as evidenced by our previous studies, in which pretreatment of neurons with 10 ng/ml of 17β-estradiol induced a sustained mitochondrial respiration in the presence of high calcium [40, 41].
Structure and neuroprotective activity predict modes of actions by estrogens
Analyses of the chemical structures of both neuroprotective and non-neuroprotective estrogens within CEE indicate that both types of estrogens contain a phenolic A ring. Thus, it raises a question with respect to the necessity of this structural moiety in allowing estrogenic neuroprotection in the brain. A representative classical nuclear ER-independent mechanism proposed by Simpkins and colleagues suggests that estrogenic neuroprotection can be conferred by a phenolic A ring in the steroid structures of estrogens, which serves as a free-radical scavenging moiety by donating a proton that saturates neurodegenerative agent-induced unpaired reactive oxygen species [42–44]. An example in support of this hypothesis is 17α-estradiol, which is 100-fold less potent than its optical isomer, 17β-estradiol, in inducing classical estrogenic actions including uterotrophic stimulation and MCF7 cell proliferation, is as potent and efficacious as 17β-estradiol in a number of neuroprotection assays . Our present study provided further evidence for 17α-estradiol's neuroprotective potency. Further, Simpkins et al demonstrated that in the hippocampal HT-22 cell line, a number of estrogens synergistically interacted with glutathione to increase the neuroprotective potency of estrogens . The interaction between glutathione and endogenous estrogen 17β-estradiol-induced neuroprotection was also found in SK-N-SH human neuroblastoma cells and primary cortical neurons . In addition, Simpkins and colleagues indicated that 17β-estradiol-induced promotion of neuronal survival in SK-N-SH cells is associated with the increased activity of neuronal nitric oxide synthase . Other potential mechanisms of actions including estrogen interactions with signal transduction pathways and induction of mitochondrion-localized anti-apoptotic proteins have also been associated with the neuroprotective effects of phenolic A ring estrogens [48, 49].
An alternative to an ER-independent mechanism of estrogen-induced neuroprotective functions is an ER subtype-dependent mechanism. ERα and ERβ are expressed in the brain with differential abundance in different brain regions . Multiple factors modulate the relative contribution of the two ER subtypes to the outcomes of neuroprotection including the type of model system, the brain region and the cell type under investigation, and even the administered dose of estrogens . For instance, in an in vivo ischemia model, Dubal and colleagues demonstrated that ERα, but not ERβ, is required for the protective effects of 17β-estradiol against ischemia-induced injury . In contrast, Sawada and Shimohama showed that ERβ mediates estrogen neuroprotection in mesencephalon dopaminergic neurons that exclusively express ERβ . Recent studies from Dorsa and colleagues demonstrated that both ERα and ERβ are involved in mediating estrogen neuroprotection against β-amyloid-induced toxicity and oxidative stress in HT-22 cells that stably express either ERα or ERβ, and that this ER-mediated neuroprotection requires the activation of the MAP kinase pathway [54, 55]. Studies from our laboratory using ER subtype-selective agonists further indicate a near equivalent contribution of ERα and ERβ to estrogen-induced neuroprotection and upregulation of the neuroprotective gene, Bcl-2, in primary hippocampal neurons .
We speculate that estrogen induction of neuroprotection can be mediated by either ER-independent or ER-dependent pathways depending upon the concentration of estrogen administered. An ER-independent anti-oxidant property is much likely the dominant factor contributing to estrogen neuroprotection at suprapharmacological doses (μM range). In contrast, at a relatively low therapeutically relevant concentration range (pM or nM range), an ER-dependent signalling pathway is likely to be the main mediator of estrogen induction of neuroprotection . Our analysis revealed that estrone at 5 nM was ineffective in enhancing neuronal defense systems in response to neurotoxic insults. In analyses by Bae and colleagues, 10–100 μM estrone protected against oxidative stress-induced cell death in mouse cortical neurons, whereas, estrone at a concentration of less than 3 μM was ineffective. Together, these data indicate that estrone is an ineffective activator of the brain ER and the associated signalling events required for estrogen neuroprotection at a low therapeutically relevant concentration, whereas, at a suprapharmacological dose, estrone can function as an effective antioxidant.
Our investigation of the intermolecular interactions of estrogens with ERα as well as the correlation between the estrogen structures with their neuroprotective activities at low concentrations comparable to their plasma levels revealed that although 4 representative estrogen analogues, 17β-estradiol, equilin, Δ8,9-dehydroestrone and estrone, bind to ERα in a similar binding mode in both conformation and orientation, their structural small variances still result in slightly different intermolecular energies with ERα, which in turn could impact their neuroprotective efficacy as evidenced by the parallel coincidence between the intermolecular energies among estrogens and their neuroprotective activities. Furthermore, we found that the presence of a phenolic A ring did not predict which estrogens, at least at a relatively low therapeutic concentration, would be full neuroprotective estrogens as multiple estrogens represented by estrone which was not protective in most conditions but contains a phenolic A ring. This suggests that the presence of a phenolic A ring in estrogens may be essential, but not entirely sufficient for estrogen-inducible neuroprotection at both the cellular plasma membrane and mitochondrial function mediated by an ER-dependent signalling pathway. In comparison, the phenolic A ring may be the crucial structural feature for allowing induction of neuroprotection by a relatively high concentration of estrogen through its anti-oxidant property. Further, we hypothesize that estrogenic neuroprotection is irrespective of activation of classical nuclear ERs but may be mediated through a non-nuclear ER-mediated signalling pathway, as supported by a increasing number of studies for a membrane-localized ER in regulating estrogen functions in neurons .
In conclusion, the present study demonstrates that select, not all, estrogens within the complex formulation of CEE at concentrations commensurate with their plasma levels achieved after an oral administration of 0.625 mg CEE in women, contribute to its neuroprotective efficacy. Coadministration of select neuroprotective estrogens can lead to a greater magnitude of neuroprotection of neuronal plasma membrane and mitochondrial function. These data provide important insights into the rational design and development of a composition of estrogen therapy to alleviate climacteric symptoms, promote neurological health and prevent age-related neurodegeneration, such as AD, in postmenopausal women. A more effective and safer brain-selective estrogen formulation than CEE could be developed through a thorough analysis of the neuroprotective efficacy of those estrogens of interest under physiological conditions.
The use of animals was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Southern California. Primary cultures of basal forebrain neurons were obtained from embryonic day 18 (E18d) Sprague-Dawley rat fetuses as previously described [15, 36]. Briefly, after dissection from the brains of the rat fetuses, the septal basal forebrain was treated with 0.02% trypsin in Hank's balanced saline solution (HBSS, 137 mM NaCl, 5.4 mM KCl, 0.4 mM KH2PO4, 0.34 mM Na2HPO4·7H2O, 10.0 mM glucose, and 10.0 mM HEPES) for 5 min at 37°C and dissociated by repeated passage through a series of fire-polished constricted Pasteur pipettes. Approximately 105 neurons/ml were plated onto poly-D-lysine (10 μg/ml)-coated 24-well and 96-well culture plates for biochemical analyses. Neurons were grown in a phenol red-free Neurobasal medium (NBM, Invitrogen) supplemented with B27, 5 U/ml penicillin, 5 μg/ml streptomycin, 0.5 mM glutamine, and 25 μM glutamate at 37°C in a humidified 10% CO2 atmosphere for the first 3 days and NBM without glutamate afterwards. Cultures grown in serum-free NBM yield approximately 99.5% neurons and 0.05% glia cells.
The estrogens were tested at concentrations commensurate with their plasma levels achieved following a single oral dose of 0.625 mg CEE, including estrone (5000 pg/ml), 17α-estradiol (10 pg/ml), 17β-estradiol (10 pg/ml), equilin (1000 pg/ml), 17α-dihydroequilin (1000 pg/ml), 17β-dihydroequilin (40 pg/ml), equilenin (300 pg/ml), 17α-dihydroequilenin (27 pg/ml), 17β-dihydroequilenin (27 pg/ml) and Δ8,9-dehydroestrone (300 pg/ml). All estrogens were purchased from Steraloids with the exception of 17α-dihydroequilenin, 17β-dihydroequilenin and Δ8,9-dehydroestrone, which were gifts from Dr. Michael Dey and Dr. Richard Lyttle of Wyeth-Ayerst Laboratories. The chemical structures of these estrogens are listed in Fig. 1. A vehicle alone-treated control group and a neurotoxin alone (β-amyloid25–35 or glutamate)-treated group were included in all experiments.
β-Amyloid25–35 purchased from Bachem was dissolved in sterile distilled water at a concentration of 1 mg/ml as a stock solution. This stock was aliquoted and stored at -20°C. Three-day-old basal forebrain neurons were pretreated with test estrogens for 4 days followed by exposure to freshly prepared 8 μg/ml β-amyloid25–35 in NBM in the presence of test estrogens for 24 hr at 37°C. Following this exposure, the culture medium was replaced with fresh β-amyloid25–35-free NBM containing test estrogens. Cultures were returned to the culture incubator and allowed to incubate for additional 24 hr prior to cell viability measurements on the following day.
Three-day-old basal forebrain neurons were pretreated with test estrogens for 4 days followed by exposure to 200 μM glutamate for 5 min at room temperature in HEPES-buffered saline solution (HBS) containing 100 mM NaCl, 2.0 mM KCl, 2.5 mM CaCl2, 1.0 mM MgSO4, 1.0 mM NaH2PO4, 4.2 mM NaHCO3, 10.0 mM glucose and 12.5 mM HEPES. Immediately following glutamate exposure, cultures were washed once with HBS and replaced with fresh NBM containing test estrogens. Cultures were returned to the culture incubator and allowed to incubate for an additional 24 hr prior to cell viability measurements on the following day.
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in all cells including neurons. It is rapidly released into the cell culture supernatant when the cell plasma membrane is damaged. Thus, the LDH level in the culture medium is a reliable biochemical index for neuronal plasma membrane damage. In this study, LDH release from the cytosol of damaged neurons into the culture medium following β-amyloid25–35 or glutamate exposure was measured using a Cytotoxicity Detection Assay (Boehringer Mannheim Biochemicals), which determines the LDH activity in the culture medium to enzymatically convert the lactate and NAD+ to pyruvate and NADH. The tetrazolium salt produced in the enzymatic reaction was then reduced to red formazan in the presence of H+, thereby allowing a colormetric detection for neuronal membrane integrity.
Intracellular ATP (adenosine triphosphate) levels were determined by a luciferin/luciferase-based method with a Bioluminescent Assay (Sigma-Aldrich), which uses ATP, a required co-factor of the luciferase reaction, producing oxyluciferin and releasing energy in the form of luminescence that is proportional to the amount of ATP present, which further signals the presence of metabolically active cells. After the culture medium supernatant was taken for the LDH assay and the rest of the medium was aspirated off, the ATP-releasing reagent was added to the culture plate to solubilize cellular membrane which allowed the release of intracellular ATP into the medium. The generated luminescence through the luciferase reaction was quantified with a TD-20e TURNER luminometer.
Neuronal metabolic viability was further determined using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Boehringer Mannheim Biochemicals) assay, which measures the enzymatic activity of the cellular mitochondrial respiratory chain through the conversion of yellow MTT to a purple formazan crystal by metabolically active cells. MTT was added to the culture plate at a final concentration of 0.5 mg/ml and incubated at 37°C for 4 hr. The reaction was stopped by the addition of 1 mM HCl in 10% SDS. Formazan crystals were dissolved overnight and absorption was measured with a spectrophotometer at 575 nm.
All the calculations were performed on a SGI Octane graphical workstation equipped with the IRIX 6.5 operating system (Silicon Graphics Inc.) using the molecular modeling software package InsightII 2000 (Accelrys Inc.). The 3D structures of estrogens were constructed and energy minimized via both molecular mechanics and dynamics simulation. The binding modes (position and orientation) of estrogens in the ligand binding site of ER were predefined by superimposing the optimized 3D structures of estrogens and the crystallographic structure of 17β-estradiol bound with its cognate receptor . Then the structure of 17β-estradiol was removed from the complex and the remaining objects were associated as a new assembly. Following the hydrogenation of the system based on a target pH of 7.0, the resultant complex, which served as the initial binding model of estrogens in complex with ER, was energetically optimized by the Discover calculation under a consistent-valence forcefield (CVFF). The initial estrogen-ER complex system was first energetically minimized with the receptor atoms fixed by consecutively executing 800 steps of steepest descents (SD) minimization and then 500 steps of conjugate gradients (CG) minimization. The refined complex system was then relaxed by removing the constraint on the residues within 7 Å of estrogens and further energetically optimized by applying 800 steps of SD and 500 steps of CG, followed by a 20 ps molecular dynamics simulation at 300 K. Conformations were written to a history file every 1 ps and the collected conformations underwent further molecular mechanics minimization by performing 800 steps of SD and 500 steps of CG. The yielded estrogen bound conformation with the lowest energy was chosen as the final binding solution.
Results from LDH, ATP and MTT assay are normalized against the data obtained from neurotoxin alone-treated cultures. Data are presented as the mean ± SEM derived from at lease three separate experiments. Statistically significant differences between groups were determined by a one-way analysis of variance (ANOVA) followed by a Newman-Keuls post hoc analysis.
The authors acknowledge the contributions of Hsiao-Pi Chu. This work was supported by grants from the National Institutes of Aging (PO1 AG1475: Project 2) and the Kenneth T. and Eileen L. Norris Foundation to RDB.
- Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC: Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002, 288 (17): 2123-2129. 10.1001/jama.288.17.2123.View ArticlePubMedGoogle Scholar
- Matthews K, Cauley J, Yaffe K, Zmuda JM: Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc. 1999, 47 (5): 518-523.View ArticlePubMedGoogle Scholar
- Steffens DC, Norton MC, Plassman BL, Tschanz JT, Wyse BW, Welsh-Bohmer KA, Anthony JC, Breitner JC: Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J Am Geriatr Soc. 1999, 47 (10): 1171-1175.View ArticlePubMedGoogle Scholar
- Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL, Schofield P, Dooneief G, Gurland B, Mayeux R: Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998, 50 (2): 368-373.View ArticlePubMedGoogle Scholar
- Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, Scarlato G, Amaducci L: Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998, 50 (4): 996-1002.View ArticlePubMedGoogle Scholar
- Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E: Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999, 52 (5): 965-970.View ArticlePubMedGoogle Scholar
- Shumaker SA, Legault C, Kuller LH, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004, 291 (24): 2947-2958. 10.1001/jama.291.24.2947.View ArticlePubMedGoogle Scholar
- Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003, 289 (20): 2651-2662. 10.1001/jama.289.20.2651.View ArticlePubMedGoogle Scholar
- Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J: Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004, 291 (24): 2959-2968. 10.1001/jama.291.24.2959.View ArticlePubMedGoogle Scholar
- Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003, 289 (20): 2663-2672. 10.1001/jama.289.20.2663.View ArticlePubMedGoogle Scholar
- Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, Farlow MR: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000, 54 (2): 295-301.View ArticlePubMedGoogle Scholar
- Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000, 283 (8): 1007-1015. 10.1001/jama.283.8.1007.View ArticlePubMedGoogle Scholar
- Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, Yu HY, Wang SJ, Liu HC: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000, 54 (11): 2061-2066.View ArticlePubMedGoogle Scholar
- Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E: Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med. 2002, 113 (7): 543-548. 10.1016/S0002-9343(02)01270-6.View ArticlePubMedGoogle Scholar
- Brinton RD, Chen S, Montoya M, Hsieh D, Minaya J, Kim J, Chu HP: The Women's Health Initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiol Aging. 2000, 21 (3): 475-496. 10.1016/S0197-4580(00)00109-3.View ArticleGoogle Scholar
- Brinton RD: Estrogen therapy for prevention of Alzheimer's disease not for rehabilitation following onset of disease: the healthy cell bias of estrogen action. Synaptic Plasticity: Basic Mechanisms to Clinical Applications. Edited by: Baudry M, Bi R, Schreiber SS. 2004, New York , Taylor & Francis Group, 131-157.Google Scholar
- Brinton RD: Impact of estrogen therapy on Alzheimer's disease: a fork in the road?. CNS Drugs. 2004, 18 (7): 405-422. 10.2165/00023210-200418070-00001.View ArticlePubMedGoogle Scholar
- Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998, 279 (9): 688-695. 10.1001/jama.279.9.688.View ArticlePubMedGoogle Scholar
- Henderson VW: Oestrogens and dementia. Novartis Found Symp. 2000, 230: 254-265.View ArticlePubMedGoogle Scholar
- Fillit HM: The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med. 2002, 162 (17): 1934-1942. 10.1001/archinte.162.17.1934.View ArticlePubMedGoogle Scholar
- Miller MM, Monjan AA, Buckholtz NS: Estrogen replacement therapy for the potential treatment or prevention of Alzheimer's disease. Ann N Y Acad Sci. 2001, 949: 223-234.View ArticlePubMedGoogle Scholar
- Nilsen J, Brinton RD: Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 2002, 143 (1): 205-212. 10.1210/en.143.1.205.View ArticlePubMedGoogle Scholar
- Nilsen J, Brinton RD: Impact of progestins on estradiol potentiation of the glutamate calcium response. Neuroreport. 2002, 13 (6): 825-830. 10.1097/00001756-200205070-00018.View ArticlePubMedGoogle Scholar
- Nilsen J, Brinton RD: Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A. 2003, 100 (18): 10506-10511. 10.1073/pnas.1334098100.PubMed CentralView ArticlePubMedGoogle Scholar
- Brinton RD, Nilsen J: Effects of estrogen plus progestin on risk of dementia. JAMA. 2003, 290 (13): 1706-10.1001/jama.290.13.1706-a.View ArticlePubMedGoogle Scholar
- Phillips SM, Sherwin BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992, 17 (5): 485-495. 10.1016/0306-4530(92)90007-T.View ArticlePubMedGoogle Scholar
- Sherwin BB: Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988, 13 (4): 345-357. 10.1016/0306-4530(88)90060-1.View ArticlePubMedGoogle Scholar
- Fedor-Freybergh P: The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl. 1977, 64: 1-91.PubMedGoogle Scholar
- Campbell S, Whitehead M: Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977, 4 (1): 31-47.PubMedGoogle Scholar
- Ditkoff EC, Crary WG, Cristo M, Lobo RA: Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991, 78 (6): 991-995.PubMedGoogle Scholar
- Bhavnani BR: Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med. 1998, 217 (1): 6-16.View ArticlePubMedGoogle Scholar
- Bhavnani BR, Woolever CA: Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. Steroids. 1991, 56 (4): 201-210. 10.1016/0039-128X(91)90083-8.View ArticlePubMedGoogle Scholar
- Data on file. Wyeth-Ayerst Laboratories.
- Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976, 2 (8000): 1403-10.1016/S0140-6736(76)91936-X.View ArticlePubMedGoogle Scholar
- Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982, 215 (4537): 1237-1239.View ArticlePubMedGoogle Scholar
- Brinton RD, Proffitt P, Tran J, Luu R: Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptor- dependent mechanism. Exp Neurol. 1997, 147 (2): 211-220. 10.1006/exnr.1997.6619.View ArticlePubMedGoogle Scholar
- Brinton RD, Tran J, Proffitt P, Montoya M: 17 beta-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res. 1997, 22 (11): 1339-1351. 10.1023/A:1022015005508.View ArticlePubMedGoogle Scholar
- Zhao L, Wu TW, Brinton RD: Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res. 2004, 1010 (1-2): 22-34. 10.1016/j.brainres.2004.02.066.View ArticlePubMedGoogle Scholar
- Chen S, Brinton RD: 17beta-estradiol protects hippocampal neurons against amyloid-induced apoptosis via a mitochondrial pathway [abstract]. Soc Neurosci Abs. 2004, 504.11.Google Scholar
- Nilsen J, Brinton RD: Mechanism of estrogen-mediated neuroprotection: regulation of mitochondial calcium and Bcl-2 expression. Proc Natl Acad Sci U S A. 2003, 100 (5): 2842-2847. 10.1073/pnas.0438041100.PubMed CentralView ArticlePubMedGoogle Scholar
- Nilsen J, Brinton RD: Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord. 2004, 3 (4): 297-313. 10.2174/1568007043337193.View ArticlePubMedGoogle Scholar
- Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F: Neuroprotection against oxidative stress by estrogens: structure- activity relationship. Mol Pharmacol. 1997, 51 (4): 535-541.PubMedGoogle Scholar
- Green PS, Gordon K, Simpkins JW: Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol. 1997, 63 (4-6): 229-235. 10.1016/S0960-0760(97)00124-6.View ArticlePubMedGoogle Scholar
- Green PS, Simpkins JW: Estrogens and estrogen-like non-feminizing compounds. Their role in the prevention and treatment of Alzheimer's disease. Ann N Y Acad Sci. 2000, 924: 93-98.View ArticlePubMedGoogle Scholar
- Green PS, Gridley KE, Simpkins JW: Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience. 1998, 84 (1): 7-10. 10.1016/S0306-4522(97)00595-2.View ArticlePubMedGoogle Scholar
- Gridley KE, Green PS, Simpkins JW: A novel, synergistic interaction between 17 beta-estradiol and glutathione in the protection of neurons against beta-amyloid 25-35-induced toxicity in vitro. Mol Pharmacol. 1998, 54 (5): 874-880.PubMedGoogle Scholar
- Wen Y, Perez EJ, Green PS, Sarkar SN, Simpkins JW: nNOS is involved in estrogen mediated neuroprotection in neuroblastoma cells. Neuroreport. 2004, 15 (9): 1515-1518. 10.1097/01.wnr.0000131674.92694.96.View ArticlePubMedGoogle Scholar
- Green PS, Yang SH, Simpkins JW: Neuroprotective effects of phenolic A ring oestrogens. Novartis Found Symp. 2000, 230: 202-213.View ArticlePubMedGoogle Scholar
- Simpkins JW, Yang SH, Wen Y, Singh M: Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. Cell Mol Life Sci. 2005, 62 (3): 271-280. 10.1007/s00018-004-4382-2.View ArticlePubMedGoogle Scholar
- Zhao L, O'Neill K, Brinton RD: Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res Brain Res Rev. 2005, 49 (3): 472-493. 10.1016/j.brainresrev.2005.01.009.View ArticlePubMedGoogle Scholar
- Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M, Rosewell KL: Estradiol is a protective factor in the adult and aging brain: understanding of mechanisms derived from in vivo and in vitro studies. Brain Res Brain Res Rev. 2001, 37 (1-3): 313-319. 10.1016/S0165-0173(01)00136-9.View ArticlePubMedGoogle Scholar
- Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM: Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A. 2001, 98 (4): 1952-1957. 10.1073/pnas.041483198.PubMed CentralPubMedGoogle Scholar
- Sawada H, Shimohama S: Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci Biobehav Rev. 2000, 24 (1): 143-147. 10.1016/S0149-7634(99)00059-7.View ArticlePubMedGoogle Scholar
- Fitzpatrick JL, Mize AL, Wade CB, Harris JA, Shapiro RA, Dorsa DM: Estrogen-mediated neuroprotection against beta-amyloid toxicity requires expression of estrogen receptor alpha or beta and activation of the MAPK pathway. J Neurochem. 2002, 82 (3): 674-682. 10.1046/j.1471-4159.2002.01000.x.View ArticlePubMedGoogle Scholar
- Mize AL, Shapiro RA, Dorsa DM: Estrogen receptor-mediated neuroprotection from oxidative stress requires activation of the mitogen-activated protein kinase pathway. Endocrinology. 2003, 144 (1): 306-312. 10.1210/en.2002-220698.View ArticlePubMedGoogle Scholar
- Zhao L, Brinton RD: Novel estrogen alternative replacement therapy targeting ERbeta for preventing neurodegeneration associated with Alzheimer's disease [abstract]. Soc Neurosci Abs. 2004, 659.9.Google Scholar
- Bae YH, Hwang JY, Kim YH, Koh JY: Anti-oxidative neuroprotection by estrogens in mouse cortical cultures. J Korean Med Sci. 2000, 15 (3): 327-336.PubMed CentralView ArticlePubMedGoogle Scholar
- Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997, 389 (6652): 753-758. 10.1038/39645.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.